<DOC>
	<DOCNO>NCT00453492</DOCNO>
	<brief_summary>The primary objective compare subject satisfaction week dose 35 mg Actonel daily dose 5 mg Actonel postmenopausal osteoporotic woman . The secondary objective measure compliance ( 50 % drug take ) , persistence , [ urinary NTx ( N-telopeptides ) ( optional ) ] .</brief_summary>
	<brief_title>Risedronate Sodium Post Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Five year great postmenopausal present diagnosis postmenopausal osteoporosis base standard clinical practice criterion . Subjects must discontinue bisphosphonates , calcitonin , fluoride , glucocorticoid ( â‰¥ 5 mg prednisone equivalent per day ) hormone replacement therapy include estrogenrelated compound least 6 month prior randomization . During study , drug permit study medication , Actonel . Other concomitant medication keep minimum , drug consider necessary subject 's welfare unlikely interfere study medication , may give discretion Investigator . Exclusion criterion : Had history cancer within past 5 year . Relatively benign skin malignancy , basal cell carcinoma squamous cell carcinoma , exclusion criterion subject remission least 6 month prior enrollment . Diagnosis hypocalcemia , hyperparathyroidism , hyperthyroidism . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>